Skip to main content
SpringerLink
Log in

Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

Tolvaptan (TLV) is a vasopressin V2 receptor antagonist that increases free water excretion. However, there are few reports of the use of TLV in pediatric patients with nephrotic syndrome (NS). The efficacy of TLV for the management of edema and hyponatremia in a 12-year-old boy with refractory NS is demonstrated. In this patient, refractory NS developed at 5 years of age, and remission was maintained with several immunosuppressive agents. He was admitted to hospital due to relapse with oliguria, edema, hypoalbuminemia, and hyponatremia. Infusion of human albumin and furosemide did not increase his urine volume, and hyponatremia worsened. Administration of TLV increased urine volume and improved his edema and hyponatremia. There were no adverse effects except for slow elevation of the serum sodium level. Serum osmolality increased gradually, and urine osmolality remained at low levels during TLV treatment. Additionally, a decrease in the sum of the urinary sodium and potassium concentrations was useful to predict the response to TLV and to assess the therapeutic effect of TLV as a biomarker for monitoring. TLV is effective for the management of fluid and electrolyte balance in pediatric NS patients. Early administration of TLV is considered a useful therapy for hyponatremia and refractory edema resistant to other diuretics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Nodari S, Jao GT, Chiong JR. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients. Int J Nephrol Renovasc Dis. 2010;3:51–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319–31.

    Article  CAS  Google Scholar 

  3. Sakaida I, Kawazoe S, Kajimura K, Saito T, Okuse C, Takaguchi K, Okada M, Okita K. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res. 2014;44:73–82.

    Article  CAS  Google Scholar 

  4. Imamura T, Kinugawa K, Minatsuki S, Muraoka H, Kato N, Inaba T, Maki H, Hatano M, Yao A, Komuro I. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J. 2014;55:131–7.

    Article  CAS  Google Scholar 

  5. Shimizu M, Ishikawa S, Yachi Y, Muraoka M, Tasaki Y, Iwasaki H, Kuroda M, Ohta K, Yachie A. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. Pediatr Nephrol. 2014;29:915–7.

    Article  Google Scholar 

  6. Meena J, Sinha A, Hari P, Bagga A. Therapy with the combination of tolvaptan and furosemide for refractory edema in nephrotic syndrome. Indian J Nephrol. 2020;30:53–5.

    Article  Google Scholar 

  7. Usberti M, Federico S, Meccariello S, Cianciaruso B, Balletta M, Pecoraro C, Sacca L, Ungaro B, Pisanti N, Andreucci VE. Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome. Kidney Int. 1984;25:422–9.

    Article  CAS  Google Scholar 

  8. Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone-a prospective study. Clin J Am Soc Nephrol. 2009;4:907–13.

    Article  Google Scholar 

  9. Delbet JD, Parmentier C, Ulinski T. Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome. Pediatr Nephrol. 2020;35:1347–50.

    Article  Google Scholar 

  10. Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patient -association between non-responders and chronic kidney disease. Circ J. 2013;77:397–404.

    Article  CAS  Google Scholar 

  11. Shoaf SE, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 2014;85:953–61.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Fukuoka Children’s Hospital, Fukuoka, Japan

    Mari Saimiya & Yoshitsugu Kaku

  2. Department of Pediatrics, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan

    Manao Nishimura

  3. Department of Pediatrics, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu-City, Fukuoka, 807-8555, Japan

    Mari Saimiya

Authors
  1. Mari Saimiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshitsugu Kaku
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manao Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mari Saimiya.

Ethics declarations

Conflict of interest

No author has a direct conflict of interest that is relevant to this study. Outside the contents of the study, Yoshitsugu Kaku received travel fees from CLS Behring.

Human and animal rights

This article does not contain any studies with human participants performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saimiya, M., Kaku, Y. & Nishimura, M. Efficacy of oral tolvaptan for severe edema and hyponatremia in a patient with refractory nephrotic syndrome. CEN Case Rep 10, 523–526 (2021). https://doi.org/10.1007/s13730-021-00601-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13730-021-00601-1

Keywords

Search

Navigation